Cargando…

The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry

BACKGROUND: Rare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and misdiagnosis. And patients are not systematically referred to expert centers...

Descripción completa

Detalles Bibliográficos
Autores principales: Villeneuve, L., Passot, G., Glehen, O., Isaac, S., Bibeau, F., Rousset, P., Gilly, F. N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316145/
https://www.ncbi.nlm.nih.gov/pubmed/28212684
http://dx.doi.org/10.1186/s13023-017-0571-y
_version_ 1782508794489602048
author Villeneuve, L.
Passot, G.
Glehen, O.
Isaac, S.
Bibeau, F.
Rousset, P.
Gilly, F. N.
author_facet Villeneuve, L.
Passot, G.
Glehen, O.
Isaac, S.
Bibeau, F.
Rousset, P.
Gilly, F. N.
author_sort Villeneuve, L.
collection PubMed
description BACKGROUND: Rare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and misdiagnosis. And patients are not systematically referred to expert centers as they should be. Clinicians and researchers also face unique challenges with these rare cancers, because it is hard to conduct adequately powered, controlled trials in such small patient population. This is how an observational patient registry constitutes a key instrument for the development of epidemiological and clinical research in the field of these rare cancers. It is the appropriate tool to pool scarce data for epidemiological research and to assess the impact of diagnostic and therapeutic strategies. We aimed to provide the outlines and the framework of the RENAPE observational registry and share our experience in the establishment of a national patient registry. RESULTS: The RENAPE observational registry has been launched in 2010 thanks to institutional supports. It concerns only patients with a histological diagnosis confirming a peritoneal surface malignancy. A web secured clinical database has been implemented based on data management procedures according to the principles of international recommendations and regulatory statements. A virtual tumor bank is linked in order to the conduct translational studies. Specialized working groups have been established to continuously upgrade and evolve the common clinical and histological data elements following the last classifications and clinical practices. They contribute also to standardize clinical assessment and homogenize practices. CONCLUSIONS: The RENAPE Registry may improve awareness and understanding of the rare peritoneal tumors into the incidence, prevalence, recurrence, survival and mortality rates, as well as treatment practices thereby enabling therapeutic intervention to be evaluated and ultimately optimized. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02834169
format Online
Article
Text
id pubmed-5316145
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-53161452017-02-24 The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry Villeneuve, L. Passot, G. Glehen, O. Isaac, S. Bibeau, F. Rousset, P. Gilly, F. N. Orphanet J Rare Dis Research BACKGROUND: Rare peritoneal cancers represent complex clinical situations requiring a specific and multidisciplinary management. Because of their rarity, lack of awareness and knowledge often leads to diagnostic delays and misdiagnosis. And patients are not systematically referred to expert centers as they should be. Clinicians and researchers also face unique challenges with these rare cancers, because it is hard to conduct adequately powered, controlled trials in such small patient population. This is how an observational patient registry constitutes a key instrument for the development of epidemiological and clinical research in the field of these rare cancers. It is the appropriate tool to pool scarce data for epidemiological research and to assess the impact of diagnostic and therapeutic strategies. We aimed to provide the outlines and the framework of the RENAPE observational registry and share our experience in the establishment of a national patient registry. RESULTS: The RENAPE observational registry has been launched in 2010 thanks to institutional supports. It concerns only patients with a histological diagnosis confirming a peritoneal surface malignancy. A web secured clinical database has been implemented based on data management procedures according to the principles of international recommendations and regulatory statements. A virtual tumor bank is linked in order to the conduct translational studies. Specialized working groups have been established to continuously upgrade and evolve the common clinical and histological data elements following the last classifications and clinical practices. They contribute also to standardize clinical assessment and homogenize practices. CONCLUSIONS: The RENAPE Registry may improve awareness and understanding of the rare peritoneal tumors into the incidence, prevalence, recurrence, survival and mortality rates, as well as treatment practices thereby enabling therapeutic intervention to be evaluated and ultimately optimized. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02834169 BioMed Central 2017-02-17 /pmc/articles/PMC5316145/ /pubmed/28212684 http://dx.doi.org/10.1186/s13023-017-0571-y Text en © The Author(s). 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Villeneuve, L.
Passot, G.
Glehen, O.
Isaac, S.
Bibeau, F.
Rousset, P.
Gilly, F. N.
The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title_full The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title_fullStr The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title_full_unstemmed The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title_short The RENAPE observational registry: rationale and framework of the rare peritoneal tumors French patient registry
title_sort renape observational registry: rationale and framework of the rare peritoneal tumors french patient registry
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5316145/
https://www.ncbi.nlm.nih.gov/pubmed/28212684
http://dx.doi.org/10.1186/s13023-017-0571-y
work_keys_str_mv AT villeneuvel therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT passotg therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT gleheno therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT isaacs therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT bibeauf therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT roussetp therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT gillyfn therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT therenapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT villeneuvel renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT passotg renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT gleheno renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT isaacs renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT bibeauf renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT roussetp renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT gillyfn renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry
AT renapeobservationalregistryrationaleandframeworkoftherareperitonealtumorsfrenchpatientregistry